Linked Data API

Show Search Form

Search Results

1127592
registered interest false more like this
date less than 2019-05-20more like thismore than 2019-05-20
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care remove filter
answering dept sort name Health and Social Care more like this
hansard heading Gender Dysphoria: Young People more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps have been taken in the last six months to reduce the waiting time for transsexual youths at the Tavistock Hospital Gender Identity Clinic. more like this
tabling member constituency Bath more like this
tabling member printed
Wera Hobhouse more like this
uin 256374 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-05-29more like thismore than 2019-05-29
answer text <p>Tavistock and Portman NHS Foundation Trust is working with NHS England to develop and implement measures to reduce waiting times. NHS England has increased funding for the Trust’s Gender Identity Development Service (GIDS) by around 150% since 2015/16, but the Trust continues to face challenges in recruiting clinical staff in GIDs with significant experience and expertise.</p><p>The service has trialled several initiatives to provide support to young people who are referred, this includes - but is not limited to:</p><p>- an ongoing recruitment drive;</p><p>- initiatives to actively manage the waiting list offering consultations to local services in complex cases while they wait for specialist input;</p><p>- consultation sessions with local mental health services and group sessions with children under 10 years of age;</p><p>- regularly reviewing communication around the waiting lists to equip young people with information which is as accurate as possible about their wait;</p><p>- reviewing policies and procedures around first appointments, for example looking at Did Not Attend (DNA) policies to ensure those offered appointments to take them up;</p><p>- giving more attention to clinically appropriate timely transitions between the Trust’s gender identity service and adult services; and</p><p>- clinician operated ‘helpline’ for urgent enquiries/concerns from young people, their families and referrers on the waiting list.</p><p>NHS England has also committed to reviewing the service specification for GIDS in 2019/20.</p>
answering member constituency Thurrock remove filter
answering member printed Jackie Doyle-Price remove filter
question first answered
less than 2019-05-29T14:26:43.147Zmore like thismore than 2019-05-29T14:26:43.147Z
answering member
4065
label Biography information for Dame Jackie Doyle-Price more like this
tabling member
4602
label Biography information for Wera Hobhouse remove filter
934121
registered interest false more like this
date less than 2018-07-03more like thismore than 2018-07-03
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care remove filter
answering dept sort name Health and Social Care more like this
hansard heading Drugs: Licensing more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will close the legal loopholes to make the market for unlicensed medicinal products less restricted. more like this
tabling member constituency Bath more like this
tabling member printed
Wera Hobhouse more like this
uin 160334 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-07-06more like thisremove minimum value filter
answer text <p>The Medicines and Health products Regulatory Agency (MHRA), the Government body responsible for the safety and licensing of medicines in the United Kingdom, is not aware of any legal loopholes for the supply of human unlicensed medicinal products.</p><p> </p><p>Before a human medicine can be marketed or sold in the UK, a number of licences are required. The product itself must have a licence called a ‘marketing authorisation’ unless an exemption applies.</p><p> </p><p>UK medicines legislation contains a provision for the supply of an unlicensed medicine (commonly known as ‘specials’) which is provided for by way of an exemption from the requirement for a marketing authorisation. In the interests of public health this exemption is narrowly drawn because these products, unlike products holding a marketing authorisation, will not have been assessed and approved against the criteria of safety, quality and efficacy in the UK.</p><p> </p><p>Unlicensed medicines can be manufactured in the UK under European Union good manufacturing practice or imported into the UK by the holder of an appropriate licence issued by the MHRA.</p><p> </p><p>Notifications prior to importation of unlicensed medicines are required and are assessed by the MHRA and objections may be raised where there are prohibitive safety or quality concerns. Any person that sells or supplies an unlicensed medicine is required to keep records and report suspected adverse drug reactions.</p>
answering member constituency Thurrock remove filter
answering member printed Jackie Doyle-Price remove filter
question first answered
less than 2018-07-06T12:28:35.367Zmore like thismore than 2018-07-06T12:28:35.367Z
answering member
4065
label Biography information for Dame Jackie Doyle-Price more like this
tabling member
4602
label Biography information for Wera Hobhouse remove filter